杨晓旭,赵昕,韩雅玲,荆全民,王效增,马颖艳,刘海伟,邓捷,邓宇阳,赵晓川

• 1:沈阳军区总医院心内科
• 2:沈阳医学院附属第二医院心内科
• 3:天津武警后勤学院附属医院心内科

摘要(Abstract)：

目的评估比伐芦定应用于急性冠状动脉综合征(ACS)行经皮冠状动脉介入治疗(PCI)患者的疗效及安全性。方法本研究入选了2012年5月至2013年2月于沈阳军区总医院接受PCI的ACS患者119例,根据PCI术中用药分为比伐芦定组60例和普通肝素组59例。主要观察住院期间出血事件,随访30 d、1年患者主要不良心血管事件(MACE)。结果两组患者基线资料比较,差异无统计学意义(P>0.05)。冠状动脉造影显示,比伐芦定组双支血管病变比例显著高于普通肝素组(36.7%比16.9%,P=0.015);三支血管病变比例较普通肝素组显著偏低(51.6%比72.9%,P=0.017);血管长病变(病变长度≥20 mm)比例显著高于普通肝素组(55.0%比32.2%,P=0.012)。比伐芦定组改善了PCI术后出血事件发生率(3.3%比8.5%,P=0.422),且PCI术后血小板下降幅度明显低于普通肝素组[(9.5±6.1)×10~9/L比(12.1±7.1)×10~9/L,P=0.036]。随访期间两组患者MACE发生率比较,差异无统计学意义(P>0.05)。结论比伐芦定在行PCI术的ACS患者中是安全、有效的。

关键词(KeyWords)： 比伐芦定;肝素;急性冠状动脉综合征;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 辽宁自然科学基金(201102241)

作者(Author): 杨晓旭,赵昕,韩雅玲,荆全民,王效增,马颖艳,刘海伟,邓捷,邓宇阳,赵晓川

参考文献(References)：

• [1]Lincoff AM,Bittl JA,Harrington RA,et al.Bivalirudin and provisional glycoprotein Ilb/IIIa blockade compared with heparin and planned glycoproteinⅡb/Ⅲa blockade during percutaneous coronary intervention;REPLACE-2 randomized trial.JAMA,2003,289:853-863.
• [2]Mehran R,Pocock SJ,Nikolsky E,et al.A risk score to predict bleeding in patients with acute coronary syndromes.J Am Coll Cardiol,2010,55:2556-2566.
• [3]Doll JA,Nikolsky E,Stone GW,et al.Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy:Pooled Analysis from REPLACE-2,ACUITY,and HORIZONS-AMI Trials.J Interv Cardiol,2009,22:453-459.
• [4]Rajagopal V,Lincoff AM,Cohen DJ,et al.Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention:an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events(REPLACE-2)trial.Am Heart J,2006,152:149-154.
• [5]Stone GW,Witzenbichler B,Guagliumi G,et al.Bivalirudin during primary PCI in acute myocardial infarction.N Engl J Med,2008,358:2218-2230.
• [6]Stone GW,Witzenbichler B,Guagliumi G,et al.Heparin plus a glycoproteinⅡb/Ⅲa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction(HORIZONS-AMI):final 3-year results from a multicenter,randomized controlled trial.Lancet,2011,377:2193-2204.
• [7]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.Circulation,2011,124:2547-2609.
• [8]Steg PG,James SK,Atar D,et al.2012 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur Heart J,2012,33:2569-2619.
• [9]向定成,顾晓龙,潘春梅,等.国产比伐卢定用于冠状动脉介入治疗术中抗凝的疗效和安全性评价.中国循环杂志,2011,26:331-334.
• [10]张萌,李娜,王蕾,等.比伐卢定在高龄急性冠脉综合征患者经皮冠状动脉介入治疗中的应用体会.中国介入心脏病学杂志,2014,22:318-321.
• [11]Han Y,Guo J,Zheng Y,et al.Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction The BRIGHT Randomized Clinical Trial.JAMA,2015,313:1336-1346.